The New Delhi-based Ochoa Labs has launched Amylofix - a new drug for obesity in the Indian market.
Company sources claimed Amylofix is an international acclaimed brand and has approval from regulatory authorities. Amylofix is a 100% natural product without any side effects. It acts through medically proven strategy to block extra calorie production through starch management.
“With the launch of this drug, we have forayed into a new area and are sure to perform well and prove our expertise in a new segment. Our previous track records in segments such as Dobesil (1999); Carnivit-E (2000) Carnivit-500 (2001), Ivermectol (2002), Essvit (2003) have provided us with the necessary confidence to introduce a new concept in the market,” Vikram Aima, chairman and managing director, Ochoa Labs said in a press release.
Amylofix blocks extra calorie production from starch and does not affect proteins, fats and other essential nutrients. The product has proven benefits in diabetic and cardiac patients. Ochoa Labs will also offer guidance on calorie management, he stated.
Ochoa’s product basket includes primarily dermatology and gynaecology drugs apart from ortho & urology. The company was founded in 1995 with a marketing network mainly in North India to begin with. It has field strength of 450 professionals in the country. The company exports to Kenya, Tanzania and plans to tap other East African Countries.